ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

We expect the company to start recording collaboration revenues ... of CRISPR Therapeutics have lost nearly 34% in the past year compared with the industry’s 14% decline, as seen in the chart ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR Therapeutics' stock ... approved by the FDA for a year now. Yet as of the latest reporting period ended September 30, 2024, it has not yet realized revenue from this treatment.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared ... the company is yet to record revenues from its sales. Also, a lack of pipeline updates ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset ... the company is yet to record revenues from its sales. Also, a lack of pipeline ...